← Markets

Altria Group, Inc.

MO · NYSE

Market closed$74.21$1.18 (+1.62%)After hours $74.06 · -0.20%

Key statistics

Previous close$73.03
Open$73.89
Day high$75.28
Day low$73.60
52-week high$75.28
52-week low$54.70
Market cap123.92B
Volume6.88M
Average volume8.55M
P/E ratio13.47
Forward P/E—
EPS5.51
Dividend yield+5.71%

Market context

Why it moved

Altria Group (MO) surged to a new 52-week high, driven by strong earnings momentum — with quarterly EPS of $1.32 beating estimates — combined with UBS raising its price target to $79 while maintaining a buy rating, boosting investor confidence in the stock.

FacebookMarketbeatModotMocoallianceFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Altria Group closed higher, outperforming a broadly lower market as investors rotated into defensive consumer staples amid tech-driven risk-off sentiment. Semiconductor weakness, AI concerns, and escalating U.S.-Iran military tensions pushed the S&P 500 lower on the day, while Altria benefited from defensive positioning — the XLP consumer staples ETF was among the few sectors in the green. Supporting the narrative, Altria continues to trade near its 52-week high of $74.56, buoyed by a strong Q1 beat ($1.32 EPS vs. $1.25 expected), raised FY2026 guidance of $5.56–$5.72, and a ~5.8% dividend yield, with multiple institutional investors recently adding to positions.

1.6158

July 17, 2026Altria Group rallied alongside consumer staples peers as investors rotated out of AI and semiconductor stocks into defensive, high-yield names amid renewed tech sector pressure. The Consumer Staples Select Sector SPDR (XLP) surged ~2.6% — its strongest session since April 2025 — while the broader S&P 500 slipped, benefiting dividend-focused stocks like Altria. Adding to the constructive backdrop, a Yahoo Finance report highlighted Altria's outlook being bolstered by new FDA rule proposals targeting foreign tobacco manufacturers, reinforcing its domestic competitive moat. With a 6.0% dividend yield, Q1 EPS of $1.32 that beat estimates, and its on! nicotine pouch brand growing 18% shipment volume, Altria closed near its 52-week high.

3.5593

July 16, 2026Altria Group closed modestly higher, supported by continued institutional accumulation and renewed investor attention as it lands on Zacks' most-searched stocks list. Multiple institutions significantly increased their MO stakes in Q1, while the company's Q1 beat — $1.32 EPS vs. $1.25 expected and $4.76B in revenue vs. $4.58B estimated — alongside raised FY2026 guidance of $5.56–$5.72 EPS keeps fundamentals constructive. A key regulatory wildcard is also in focus: public health groups sued the FDA over its new flavored e-cigarette/nicotine pouch policy, which Altria publicly endorsed as critical to combating the illicit market — an outcome that could shape the company's next-gen product runway heading into its July 30 earnings report.

0.5131

July 15, 2026Altria Group declined despite a broadly higher market on a cooler-than-expected CPI report, as the stock pulled back from near its 52-week high of $74.56 amid mixed institutional sentiment and a consensus analyst price target of $70.78 — essentially at current levels. The selloff came as investors appeared to book profits following a strong run (shares up ~25% year-to-date), with some concern that the stock looks modestly overvalued relative to fair-value models, even as Q1 results beat estimates ($1.32 EPS vs. $1.25 expected) and FY2026 guidance was reaffirmed at $5.56–$5.72 EPS. The consumer defensive sector (XLP) also closed lower, underperforming the broader S&P 500, as defensives gave back ground in a risk-on session driven by tech and growth stocks responding to the soft inflation print.

-2.3793

July 14, 2026Altria Group closed essentially flat as investors balanced the company's strong fundamental backdrop against a broader market selloff triggered by renewed U.S.-Iran military tensions that sent oil prices surging. Key investor focus centers on the upcoming Q2 2026 earnings report (expected July 30, with analysts projecting $1.50 EPS), while a recent Bank of America note raised estimates and maintained an $82 price target following favorable FDA regulatory developments — including authorization of 20 ZYN variants and relaxed enforcement on nicotine pouches — that helped the tobacco sector outperform most consumer staples sub-groups in Q2. With a 5.9% dividend yield, a 60th dividend increase in 56 years, and MO shares up ~24% over the past year, income-oriented investors continue to view the stock as a defensive holding amid market rotation away from AI/tech.

0.1114

July 11, 2026Altria Group closed modestly higher, edging up as investors weighed a broadly positive backdrop for tobacco stocks amid a sector re-rating narrative. A Wall Street Journal report highlighted that tobacco companies pivoting to smoke-free products are "rejoining polite society" with institutional investors returning after years of ESG-driven exclusions — a tailwind that has benefited peers Philip Morris and BAT more directly, given their larger smoke-free revenue mix. For Altria specifically, attention is building ahead of its Q2 2026 earnings on July 30, with analysts expecting EPS of $1.50, up ~4% year-over-year, following a strong Q1 beat. Today also marked the payment date for Altria's $1.06 quarterly dividend (~5.9% annualized yield), reinforcing its appeal as a Dividend King in a market rotating toward income and defensive assets. UBS recently set a $79 price target, though the consensus remains Hold at $70.78.

0.2514

July 10, 2026Altria Group declined as geopolitical-driven market volatility and sector-wide headwinds in consumer staples weighed on the stock, with the XLP ETF also finishing lower on the day. Investors are navigating a complex narrative around the company: while Altria's Q1 earnings beat expectations (EPS $1.32 vs. $1.25 est.) and a $1.06 quarterly dividend is set to pay July 10, the broader tobacco story is shifting. Peer Philip Morris gained fresh attention after the FDA granted ZYN nicotine pouches a Modified Risk designation, spotlighting the accelerating industry pivot to smoke-free products — an area where Altria, still heavily cigarette-dependent, faces strategic pressure. UBS recently raised its price target to $79, but analyst sentiment remains mixed with a consensus Hold and $70.78 target.

-1.6756

July 9, 2026Altria Group closed essentially flat amid a broader defensive rotation as geopolitical tensions—President Trump declaring the U.S.-Iran ceasefire "over" and sparking an oil price surge—drove investors into consumer staples while tech and cyclicals sold off. UBS raised its price target on Altria to $79 (from $76), maintaining a Buy rating and citing improving EPS growth prospects, favorable FDA guidance on next-generation products like on! pouches, and potential for guidance upgrades. With a $1.06 quarterly dividend due July 10th and a 5.8% yield, Altria's defensive profile and smoke-free product expansion narrative continue to attract income-focused investors even as Marlboro volume pressures persist.

-0.2056

Yahoo Finance Singapore · July 17, 2026Altria (MO) Gains As Market Dips: What You Should KnowThe Globe and Mail · July 17, 2026Yielding 6.5%, Is Altria Stock an Excellent Dividend Stock to Buy?Investing.com · July 17, 2026Altria Group stock hits 52-week high at $74.60MarketBeat · July 17, 2026Altria Group (NYSE:MO) Reaches New 12-Month High - Here's WhyMoomoo · July 17, 2026Goldman Sachs Maintains Altria(MO.US) With Buy Rating, Maintains Target Price $77Yahoo Finance Singapore · July 16, 2026Altria Group, Inc. (MO) is Attracting Investor Attention: Here is What You Should KnowBarchart.com · July 16, 2026Altria to Host Webcast of 2026 Second-Quarter and First-Half ResultsMarketWatch · July 15, 2026Altria Group Inc. stock underperforms Tuesday when compared to competitors
Benzinga · July 7, 2026UBS Maintains Buy on Altria Group, Raises Price Target to $79
Mt Newswire · July 7, 2026UBS Adjusts Price Target on Altria Group to $79 From $76
Mt Newswire · June 26, 2026Philip Morris, Other Tobacco Stocks Rise After FDA Proposes Foreign Tobacco Regulations
Mt Newswire · May 28, 2026Altria Group Insider Sold Shares Worth $418,318, According to a Recent SEC Filing
Mt Newswire · May 27, 2026Jefferies Adjusts Price Target on Altria to $60 From $50, Maintains Underperform Rating
Mt Newswire · May 21, 2026Altria Subsidiary USSTC Plans Facility Relocation
Benzinga · May 21, 2026Altria Group's U.S. Smokeless Tobacco Subsidiary To Shift Production Operations From Nashville To New Site In Hopkinsville, Kentucky; Nashville Operations Anticipated To Shut Down Completely In Early 2028
Benzinga · May 18, 2026Altria Group Elects Salvatore Mancuso As CEO Effective May 14, 2026

Peers

S&P 500SPX · $7,457.69-1.01%Philip Morris International Inc.PM · $192.98+1.65%British American Tobacco p.l.c.BTI · $62.84-0.51%Japan Tobacco Inc.2914.T · ¥6,347.00+2.45%Imperial Brands PLCIMB.L · 2,870.00+2.32%Universal CorporationUVV · $53.14+0.23%Turning Point Brands, Inc.TPB · $82.84-0.67%RLX Technology Inc.RLX · $2.05+0.99%Cronos Group Inc.CRON · $2.79+1.45%22nd Century Group, Inc.XXII · $4.33+0.93%Ispire Technology Inc.ISPR · $1.75-6.91%Anheuser-Busch InBev SA/NVBUD · $80.57-1.09%